Volume 20, Number 6—June 2014
Research
Characteristics of Patients with Mild to Moderate Primary Pulmonary Coccidioidomycosis
Table 1
Characteristics of 36 patients with primary pulmonary coccidioidomycosis, Arizona, USA, March 1, 2010–October 31, 2012*
Characteristic | Total, N = 36 | Antifungal treatment |
p value | |
---|---|---|---|---|
Yes, n = 20 | No, n = 16 | |||
Sex, no. (%) | ||||
M | 16 (44) | 11 (55) | 5 (31) | 0.15† |
F |
20 (56) |
9 (45) |
11 (69) |
0.15† |
Age, y, median (range) |
53 (21–79) |
52 (28–79) |
53 (21–68) |
0.48‡ |
Race/ethnicity, no. (%) | 0.65† | |||
White | 33 (92)§ | 18 (90) | 15 (94) | |
Hispanic | 1 (3) | 1 (5) | 0 | |
Asian |
2 (6) |
1 (5) |
1 (6) |
|
Follow-up time, median (IQR), wk |
24 (24.0–24.0) |
24 (21.5–24.0) |
24 (24.0–24.0) |
|
Concurrent illness¶ | ||||
Rheumatologic, no. (%)# | 1 (3) | 1 (5) | 0 | 0.35† |
Prior remote cancer, no recurrence, no./total (%)# |
3/35 (9) |
2/19 (11) |
1 (6) |
0.65† |
Employment | ||||
Employed at time of coccidioidomycosis, no. (%) | 22 (61) | 14 (70) | 8 (50) | 0.22† |
Illness resulted in work absences, no. (%) | 18/22 (82) | 12/14 (86) | 6/8 (75) | 0.53† |
Days absent, median no. (IQR), [range] |
10 (5–14) [1–28] |
10 (5–15) [2–28] |
7 (4–12) [1–13] |
0.32‡ |
School attendance | ||||
Attending at time of coccidioidomycosis, no. (%) | 3 (8) | 2 (10) | 1 (6) | 0.68 |
Illness resulted in absences, no./total (%) |
1/3 (33) |
0 |
1/1 (100) |
0.08 |
Coccidioidal symptoms, ever present, no. (%) | ||||
Fatigue | 36 (100) | 20 (100) | 16 (100) | >0.99† |
Fever | 31 (86) | 19 (95) | 12 (75) | 0.08† |
Chills | 32 (89) | 19 (95) | 13 (81) | 0.19† |
Cough | 34 (94) | 18 (90) | 16 (100) | 0.19† |
Night sweats | 29 (81) | 17 (85) | 12 (75) | 0.45† |
Headache | 29 (81) | 16 (80) | 13 (81) | 0.93† |
Chest pain | 25 (69) | 15 (75) | 10 (62) | 0.52† |
Arthralgia | 25 (69) | 13 (65) | 12 (75) | 0.59† |
Rash |
23 (64) |
12 (60) |
11 (69) |
0.58† |
Coccidioidal symptoms score at enrollment, median (IQR) |
5.0 (3.0–7.0) |
5.5 (5.0–7.5) |
4.0 (3.0–5.0) |
0.02‡ |
Diagnostic test results | ||||
Median chest radiograph score at enrollment | 2.0 | 2.0 | 2.0 | 0.72‡ |
Positive serologic results at enrollment, no./total (%) | ||||
EIA IgM | 34/35 (97) | 18/19 (95) | 16/16 (100) | 0.35† |
EIA IgG | 26/35 (74) | 12/19 (63) | 14/16 (88) | 0.1† |
ID IgM | 14/36 (39) | 7/20 (35) | 7/16 (44) | 0.59† |
ID IgG | 19/35 (53) | 10/20 (50) | 9/16 (56) | 0.71† |
Positive IgG by CF | 12/32 (38) | 6/16 (38) | 6/16 (38) | >0.99† |
*IQR, interquartile range; EIA, enzyme immunoassay; ID, immunodiffusion; CF, complement fixation.
†By χ2 test.
‡By Wilcoxon rank-sum test.
§95% CI for White race was 77.5%–98.2%.
¶No patients had pulmonary, cardiovascular, kidney, or liver disease.
#Patient was not receiving any immunosuppressive treatment or chemotherapy.